Journal of Adolescent Health commentary reports 7-OH withdrawal in a 17-year-old

Why it matters

The commentary documents a case of severe withdrawal after a teenager stopped using 7-OH. It can help clinicians recognize a possible presentation, but one case cannot estimate how common it is or establish how well a treatment works more broadly.

The big picture

The Journal of Adolescent Health commentary pairs one clinical case with a discussion of young people's access to concentrated 7-OH products. Its authors urge adolescent-care providers to ask about exposure and support patients who use these products.

Key findings

• The commentary describes a 17-year-old who developed tachycardia, sweating, diarrhea, and anxiety after abruptly stopping 7-OH.
• He had started using 7-OH from a vape shop socially about one month earlier; his use escalated and he made two unsuccessful attempts to stop before seeking care.
• The patient received a short course of sublingual buprenorphine at daily doses of 2 to 8 mg and was referred for ongoing mental health care.
• The case was presented at the Society for Adolescent Health and Medicine conference in March 2026; the journal commentary appeared online September 23.

What they say

The authors write that "AYA providers have a key role in identifying, counseling, and supporting young people exposed to emerging opioids such as 7-OH," using AYA to mean adolescent and young adult.

Bottom line

The case supports asking adolescent patients about concentrated 7-OH use, while broader evidence is still needed.